External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

Hawaiian Eye 2024

-
Coming soon
08:16 PM
Duration 6mins Session: Abstract Presentations
Faster Time to Retinal Fluid Control With Faricimab▼ vs Aflibercept in Patients With DME in the Phase 3 YOSEMITE/RHINE Trials
Talcott K*, Finn A, Walter S, Lanzetta P, Rachitskaya A, Amador M, Camino A, Gibson K, Idowu O, Mar F, Tang Y

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
08:03 PM
Duration 6mins Session: Abstract Presentations
Real-World Clinical and Anatomical Outcomes in Patients With Neovascular Age-Related Macular Degeneration Treated With Faricimab▼: The FARETINA-AMD Study
Ali F*, Tabano D, Garmo V, Borkar D, Leng T, Shaia J, Kuo B, Myers R, LaPrise A, Ali F, Singh R

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
08:11 PM
Duration 6mins Session: Abstract Presentations
Faricimab▼ Extended Dosing in the Phase 3 YOSEMITE/RHINE and TENAYA/LUCERNE Trials
Singer M*, Amador M, Hill L, Patel S, Sim D, Gibson K, Margaron P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
08:19 PM
Duration 6mins Session: Abstract Presentations
Real-World Clinical and Anatomical Outcomes in Patients With Diabetic Macular Edema Treated With Faricimab▼: The FARETINA-DME Study
Borkar D*, Tabano D, Garmo V, Leng T, Shaia J, Kuo B, Myers R, LaPrise A, Ali F, Singh R

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
08:03 PM
Duration 6mins Session: Abstract Presentations
Impact of Faricimab▼ vs Aflibercept on Epiretinal Membrane Formation Over 2 Years in Eyes With DME in the YOSEMITE/RHINE Phase 3 Trials
Nudleman E*, Jaffe G, Ogura Y, Deak G, Gibson K, Schmidt-Erfurth U, Wang T, Westenskow P, Willis J

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
08:19 PM
Duration 6mins Session: Abstract Presentations
Biomarkers for vascular stability and inflammation demonstrate the benefit of dual Ang-2/VEGF-A inhibition with faricimab▼ Phase 3 trials in DME
Graff J*, Patel K, Wang T, Willis J, Gibson K, Mar F, Amador M, von Schulthess E, Maunz A, Glittenberg C

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
08:27 PM
Duration 6mins Session: Abstract Presentations
Changes in Intraocular Angiopoietin-2 and VEGF-A Following Faricimab▼ Treatment in nAMD and DME
Rahimy E*, Avery R; Cheung G, Bogman K, Stoilov I, Diack C

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar